A recurrence-free survivor with chemotherapy-refractory small cell lung cancer after pneumonectomy

Pan, Yong; Kong, Feng-Wei; Wang, Heng; Wang, Xiang; Zhang, Hui; Wu, Wenbin; Zhang, Miao

doi:10.1097/md.0000000000008922

Cited by 4 publications

(8 citation statements)

References 20 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 16 , 17 The current results also suggested that a lower dose might be a potential option in patients with advanced SCLC. Two recent reports described the use of apatinib combined with pneumonectomy or/and radiotherapy in two patients with relapsed SCLC, 18 , 19 while other studies reported on the use of apatinib as maintenance therapy in patients with stable SCLC after induction chemotherapy. 20 , 21 Low-dose apatinib might thus be a possible therapeutic choice in patients with advanced SCLC.…”

Section: Discussionmentioning

confidence: 99%

“… 14 – 17 We previously reported that low-dose apatinib (250 mg/day) monotherapy resulted in similar PFS to higher-dose apatinib (500–750 mg/day) in patients with NSCLC, 16 , 17 and was associated with fewer adverse effects in these studies. In a recent case report, apatinib (425 mg/day) combined with pneumonectomy and/or radiotherapy was used in two patients with relapsed SCLC, 18 , 19 and two other studies also reported on the use of apatinib as maintenance therapy in patients with stable SCLC after induction chemotherapy. 20 , 21 Another report used higher-dose apatinib (500 mg/day) in patients with extensive SCLC.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Low-dose apatinib monotherapy in advanced chemotherapy-refractory small cell lung cancer: a case series and literature review

et al. 2019

View full text Add to dashboard Cite

The therapeutic regimen for small cell lung cancer (SCLC) has changed little in the past several decades. Apatinib is a small molecule inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase. Apatinib has demonstrated efficacy against advanced gastric cancer and breast cancer, and recent studies have also reported its successful use in non-SCLC; however, its efficacy in SCLC remains unclear. In this study, we used apatinib as salvage therapy for chemotherapy-refractory SCLC. Five male patients with advanced SCLC were administered oral apatinib (250 mg/day) as 2nd- to 4th-line treatment. One patient showed a partial response to apatinib, one showed stable disease, and three patients showed progressive disease. The progression-free survival durations in the patients with stable disease and partial response were 1.5 and 3 months, respectively. Only three patients showed adverse effects, including mild hypertension, vomiting, and hand–foot syndrome, respectively, all of which were manageable. Apatinib might thus be a salvage option in patients with advanced SCLC after chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Low-dose apatinib monotherapy in advanced chemotherapy-refractory small cell lung cancer: a case series and literature review

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Therefore, the 5-year survival rate remains low at <7% overall; most patients survive for only <1 year after diagnosis (7). There had been few improvements in SCLC standard of care management in the decades prior to the IMpower133 results, which demonstrated survival benefit with the addition of the anti-PD-L1 agent atezolizumab to platinum-based chemotherapy for patients with extensive-stage SCLC (8).…”

Section: Introductionmentioning

confidence: 99%

Effects of Surgery on Survival of Early-Stage Patients With SCLC: Propensity Score Analysis and Nomogram Construction in SEER Database

et al. 2020

View full text Add to dashboard Cite

Purpose: We aimed to assess the survival benefit of surgery for patients with stage IA-IIB small cell lung cancer (SCLC) and construct a nomogram for predicting overall survival (OS). Methods: Patients who had been diagnosed with stage IA-IIB SCLC between 2004 and 2014 and who had received active treatment were selected from the Surveillance, Epidemiology, and End Results database. The primary endpoint was OS. Cox proportional hazards models and propensity score (PS) analyses were used to compare the associations between surgery and OS. The probability of 1-and 3-year OS was predicted using a nomogram. Results: We reviewed 2,246 patients. The median OS of the surgery and non-surgery groups was 35 months and 19 months, respectively. Multivariable Cox proportional hazards models showed a survival benefit in the surgery group (hazards ratio [HR], 0.642; 95% confidence interval [CI], 0.557-0.740; P < 0.001). To balance the between-group measurable confounders, the impact of surgery on OS was assessed using PS matching. After PS matching, OS analysis still favored surgical resection. The PS-stratification, PS-weighting, and PS-adjustment models showed similar results to demonstrate a statistically significant benefit for surgery. Further, the nomogram was well calibrated and had good discriminative ability (Harrell's C-index = 0.645). Conclusion: Our analysis suggests that surgery is a viable option for patients with early-stage SCLC. Our nomogram is a viable tool for quantifying treatment trade-off assumptions and may assist clinicians in decision-making. Future work is needed to validate our results and improve our tools.

show abstract

“…This study highlighted the importance of performing lobectomy for resectable C-SCLC patients. Pan et al and Zeng et al also confirmed that surgical removal of the primary lesion in patients with SCLC is safe and effective, even when a larger extent of resection is necessary [20,21].…”

Section: Description Of the State Of Knowledgementioning

confidence: 86%

“…Of these, only manuscrpits dealing directly with surgical pulmonary resection in SCLC were selected. Based on these criteria, 14 publications were identified and included in the review [8][9][10][11][12][13][14][15][16][17][18][19][20][21](Tab. 1).…”

Section: Review Methodsmentioning

confidence: 99%

The role of pulmonary resection in early stage small cell lung cancer

Sagan¹,

Galek²,

Prystupa³

2021

J Pre Clin Clin Res.

View full text Add to dashboard Cite

Introduction and Objective. For many decades, small-Cell Lung Cancer (SCLC) has been considered a non-surgical disease and is traditionally managed by chemo-and radiotherapy. However, recent advances in early detection of pulmonary lesions have made it possible to detect small cell lung cancer at a very early stage of development. The aim of this review was to assess the current state of knowledge on the role of surgical pulmonary resection in patients with early stage SCLC, and to determine the optimal diagnostic and therapeutic strategy for patients with pulmonary nodules suspected for SCLC. Review Methods. A literature search of the PubMed database was conducted using the key words: 'small cell lung cancer pulmonary resection not[non]' in the last 5 years. 99 manuscripts were found. Of these, only dealing directly with surgical pulmonary resection in SCLC were selected. Based on these criteria, 14 publications were identified and included in the review. Brief description of the state of knowledge. Current scientific and clinical data reveal that surgical resection offers patients with SCLC considerable therapeutic benefits with favourably high overall survival rates. Analyzed reports showed that the local relapse rate in patients after surgical resection was significantly lower than in the non-surgical group. Furthermore, definitive surgical resection with adjuvant chemotherapy resulted in improved survival for patients with early stage SCLC, when compared to conservative approach. Summary. Pulmonary resection of an early stage SCLC as a component of combined treatment offers considerable therapeutic benefits, among which almost 100% local control is of the greatest importance. Up-to-date clinical strategies strongly support the recommendation that peripheral pulmonary lesions suspected to be malign, should be surgically resected, unless serious contraindications are indicated.

show abstract

A recurrence-free survivor with chemotherapy-refractory small cell lung cancer after pneumonectomy

Cited by 4 publications

References 20 publications

Low-dose apatinib monotherapy in advanced chemotherapy-refractory small cell lung cancer: a case series and literature review

Low-dose apatinib monotherapy in advanced chemotherapy-refractory small cell lung cancer: a case series and literature review

Effects of Surgery on Survival of Early-Stage Patients With SCLC: Propensity Score Analysis and Nomogram Construction in SEER Database

The role of pulmonary resection in early stage small cell lung cancer

Contact Info

Product

Resources

About